# How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

> **NCT03370861** · — · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 54 (actual)

## Conditions studied

- Autoimmunity
- Melanoma
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma of the Skin
- Basal Cell Carcinoma
- Skin Cancer

## Interventions

- **BIOLOGICAL:** Immunotherapy

## Key facts

- **NCT ID:** NCT03370861
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study to be closed.
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370861, "How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03370861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*